Neuland Laboratories opens new facility in Hyderabad for API Corporation
Will manufacture competitively-priced pharmaceutical APIs and intermediates for APIC
Neuland Laboratories, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), intermediates and contract manufacturing services, has opened a new manufacturing facility at its existing complex in Pashamylaram, Hyderabad, India.
The plant has been built as part of the company's collaboration agreed last year with Tokyo-based API Corporation (APIC), a healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs, along with fine chemicals and reagents. The new manufacturing facility in India is APIC's first outside Japan.
APIC helped fund the facility, which Neuland is dedicating to production for APIC's customers in Japan.
'This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland,' said Kiyoshi Kondo, President and CEO of APIC.
D R Rao, Chairman and Managing Director of Neuland Labs, added that the partnership would raise Neuland’s profile as a quality supplier of APIs and intermediates to the Japanese market.
